Your browser is no longer supported. Please, upgrade your browser.
Royalty Pharma plc
Index- P/E31.99 EPS (ttm)1.31 Insider Own17.50% Shs Outstand398.52M Perf Week-1.04%
Market Cap25.29B Forward P/E14.13 EPS next Y2.96 Insider Trans-7.35% Shs Float101.25M Perf Month-13.88%
Income495.20M PEG4.00 EPS next Q0.67 Inst Own60.70% Short Float17.92% Perf Quarter-18.30%
Sales2.12B P/S11.91 EPS this Y-66.60% Inst Trans25.57% Short Ratio6.28 Perf Half Y-2.15%
Book/sh12.09 P/B3.46 EPS next Y11.76% ROA3.20% Target Price52.29 Perf Year-
Cash/sh4.39 P/C9.54 EPS next 5Y8.00% ROE10.70% 52W Range34.80 - 56.50 Perf YTD-16.34%
Dividend0.68 P/FCF- EPS past 5Y- ROI14.70% 52W High-25.69% Beta-
Dividend %1.62% Quick Ratio8.80 Sales past 5Y- Gross Margin- 52W Low20.65% ATR1.35
Employees51 Current Ratio8.80 Sales Q/Q-68.50% Oper. Margin73.70% RSI (14)40.84 Volatility3.03% 3.34%
OptionableYes Debt/Eq1.21 EPS Q/Q-89.10% Profit Margin23.30% Rel Volume0.16 Prev Close41.87
ShortableYes LT Debt/Eq1.21 EarningsFeb 17 BMO Payout22.90% Avg Volume2.89M Price41.99
Recom2.40 SMA20-2.16% SMA50-7.14% SMA200-4.75% Volume324,424 Change0.27%
Nov-09-20Upgrade UBS Neutral → Buy $52 → $51
Jul-14-20Initiated Evercore ISI In-line
Jul-13-20Initiated UBS Neutral $52
Jul-13-20Initiated SunTrust Buy $56
Jul-13-20Initiated Morgan Stanley Equal-Weight $51
Jul-13-20Initiated JP Morgan Neutral $50
Jul-13-20Initiated Goldman Neutral $47
Jul-13-20Initiated Cowen Outperform $55
Jul-13-20Initiated Citigroup Neutral $50
Jul-13-20Initiated BofA Securities Buy $55
Apr-15-21 09:00AM  
Apr-08-21 07:40AM  
Apr-01-21 07:30AM  
Mar-30-21 08:00AM  
Mar-11-21 02:37PM  
Feb-17-21 12:30PM  
Feb-15-21 05:30AM  
Jan-29-21 11:35PM  
Jan-22-21 08:00AM  
Jan-19-21 08:30AM  
Jan-08-21 08:05AM  
Jan-07-21 04:15PM  
Dec-23-20 03:16PM  
Dec-22-20 08:30AM  
Dec-21-20 08:12AM  
Dec-17-20 04:29PM  
Dec-07-20 08:45AM  
Dec-04-20 04:31PM  
Nov-16-20 03:39AM  
Nov-10-20 05:40PM  
Nov-02-20 07:30AM  
Oct-20-20 04:32PM  
Oct-19-20 09:00AM  
Oct-15-20 11:45PM  
Oct-13-20 04:10PM  
Oct-02-20 07:00AM  
Sep-16-20 11:42AM  
Sep-02-20 04:25PM  
Aug-25-20 08:14AM  
Aug-19-20 09:00AM  
Aug-12-20 07:00AM  
Aug-07-20 09:40AM  
Aug-03-20 04:15PM  
Jul-20-20 04:15PM  
Jul-17-20 12:00PM  
Jul-15-20 04:33PM  
Jul-13-20 10:16AM  
Jul-02-20 01:02PM  
Jul-01-20 01:48PM  
Jun-30-20 10:40AM  
Jun-27-20 07:13PM  
Jun-26-20 04:42PM  
Jun-25-20 07:01PM  
Jun-22-20 06:10PM  
Jun-18-20 04:15PM  
Jun-17-20 09:55AM  
Jun-16-20 06:21PM  
Jun-15-20 11:29PM  
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and 5 development-stage product candidates in various therapeutic areas, such as rare disease, oncology, neurology, infectious disease, cardiology, and diabetes. The company has royalties on various product, such as Cystic fibrosis franchise, including Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio; HIV franchise comprising Atripla, Truvada, Emtriva, Complera, Stribild, Genvoya, Descovy, Odefsey, Symtuza, and Biktarvy; Tradjenta, Onglyza, Kombiglyze, Galvus, Eucreas, and Nesina; Tysabri, Imbruvica, Xtandi, Promacta, Farxiga/Onglyza, Prevymis, Emgality, Crysvita, Erleada, IDHIFA, Trodelvy, Nurtec ODT, Tazverik, and Evrysdi; and other products, such as Bosulif, Cimzia, Conbriza/Fablyn/Viviant, Entyvio, Lexiscan, Mircera, Myozyme, Nesina, Priligy, and Soliqua, as well as Tecfidera, Letairis, Lyrica, Remicade, Humira, Prezista, Rotateq, and Thalomid. Royalty Pharma plc was founded in 1996 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lloyd George W.EVP, Investments & GCApr 14Sale42.1369,8222,941,92050,000Apr 16 05:57 PM
Reddoch James F.EVP, Research & InvestmentsApr 14Sale42.1055,7142,345,593200,000Apr 16 05:56 PM
Reddoch James F.EVP, Research & InvestmentsApr 12Sale42.3235915,193255,714Apr 14 07:51 AM
Lloyd George W.EVP, Investments & GCApr 12Sale42.3244919,00263,924Apr 14 07:52 AM
Lloyd George W.EVP, Investments & GCMar 22Sale46.3254,7292,535,22664,013Mar 24 05:25 PM
Reddoch James F.EVP, Research & InvestmentsMar 22Sale46.3243,9272,034,519256,073Mar 24 05:25 PM
Coyne Terrance P.EVP & CFOMar 03Sale44.78100,0004,478,450200,000Mar 05 07:04 PM
Lloyd George W.EVP, Investments & GCMar 02Sale46.94125,0005,867,14875,000Mar 04 07:03 PM
Reddoch James F.EVP, Research & InvestmentsMar 02Sale46.92100,0004,692,158300,000Mar 04 07:02 PM
Coyne Terrance P.EVP & CFOMar 02Sale46.94100,0004,694,090300,000Mar 04 07:00 PM
Fernandez Henry ADirectorFeb 25Buy46.8325,7001,203,48025,700Feb 26 07:46 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerDec 18Sale44.02101,0504,448,22138,714,280Dec 18 02:36 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerDec 17Sale43.927,200,000316,224,00038,815,330Dec 18 02:36 PM
RIGGS RORY BDirectorOct 20Sale42.00463,20019,454,4000Oct 22 09:48 PM
ADAGE CAPITAL PARTNERS GP, L.L10% OwnerJun 18Buy28.003,000,00084,000,00046,015,330Jun 22 05:31 PM
Coyne Terrance P.EVP & CFOJun 18Buy28.001,45040,6001,450Jun 23 09:21 PM
Coyne Terrance P.EVP & CFOJun 18Buy28.001,50042,0001,500Jun 23 09:21 PM
RIGGS RORY BDirectorJun 18Buy28.0015,000420,00015,000Jun 23 09:14 PM
Hite ChristopherEVP & Vice ChairmanJun 18Buy28.0070,0001,960,00070,000Jun 23 09:13 PM
FORD WILLIAM EDirectorJun 18Buy28.001,500,00042,000,0001,500,000Jun 22 09:55 PM
Legorreta Pablo G.CEO, Chairman of the BoardJun 18Buy28.0020,000560,00010,000Jun 22 09:55 PM
Lloyd George W.EVP, Investments & GCJun 18Buy28.0011,200313,60011,200Jun 22 09:54 PM
Lloyd George W.EVP, Investments & GCJun 18Buy28.003,00084,0003,000Jun 22 09:54 PM
Giuliani Mario GermanoDirectorJun 18Buy28.0050,0001,400,00050,000Jun 22 09:47 PM